Novo Holdings A S Buys 556,970 Shares of Pharvaris (NASDAQ:PHVS)

Novo Holdings A S increased its stake in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 47.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,725,000 shares of the company's stock after purchasing an additional 556,970 shares during the period. Pharvaris makes up approximately 1.6% of Novo Holdings A S's investment portfolio, making the stock its 19th largest holding. Novo Holdings A S's holdings in Pharvaris were worth $32,430,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Deerfield Management Company L.P. Series C grew its stake in shares of Pharvaris by 31.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company's stock worth $26,269,000 after purchasing an additional 335,687 shares during the period. Sofinnova Investments Inc. lifted its holdings in Pharvaris by 2.9% during the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company's stock worth $11,309,000 after acquiring an additional 16,862 shares in the last quarter. Blackstone Inc. bought a new position in Pharvaris during the fourth quarter worth about $2,805,000. venBio Partners LLC lifted its holdings in Pharvaris by 15.4% during the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company's stock worth $137,992,000 after acquiring an additional 654,832 shares in the last quarter. Finally, Commodore Capital LP bought a new position in Pharvaris during the fourth quarter worth about $22,440,000.

Analyst Upgrades and Downgrades

Separately, Oppenheimer lifted their target price on Pharvaris from $38.00 to $42.00 and gave the stock an "outperform" rating in a report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, Pharvaris currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.60.

Pharvaris Trading Down 1.6 %

Shares of Pharvaris stock traded down $0.29 during trading on Monday, reaching $18.25. The stock had a trading volume of 24,075 shares, compared to its average volume of 88,962. The company has a market capitalization of $581.08 million, a price-to-earnings ratio of -6.92 and a beta of -3.10. The stock has a fifty day moving average price of $18.38 and a two-hundred day moving average price of $19.68. Pharvaris has a 52 week low of $15.00 and a 52 week high of $33.00.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.02). On average, equities analysts forecast that Pharvaris will post -2.58 EPS for the current fiscal year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.